Gossamer Bio

Dilution score: 18/100 (LOW), 24.0 months cash

Short interest: 17.98% of float, squeeze risk: MODERATE

374 PubMed publications found for Gossamer Bio

Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.

The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial.

Sex-specific autosomal susceptibility loci in systemic sclerosis: a genome-wide association study.

Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis.

Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials.

Dilution score: 32/100 (MEDIUM), 12.2 months cash

373 PubMed publications found for Gossamer Bio

Short interest: 17.61% of float, squeeze risk: MODERATE

372 PubMed publications found for Gossamer Bio

Understanding the burden of pulmonary arterial hypertension among patients and caregivers through narrative medicine: data from Italian multicentre observational INSPECTIO study.

Short interest: 17.62% of float, squeeze risk: MODERATE

Short interest: 18.88% of float, squeeze risk: MODERATE

Dilution score: 32/100 (MEDIUM), 17.6 months cash

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

370 PubMed publications found for Gossamer Bio

SW convergence: 50/100 (Neutral), 2 bullish / 1 bearish signals

Short interest: 18.96% of float, squeeze risk: MODERATE

369 PubMed publications found for Gossamer Bio

Practical Considerations for Managing Transitions from Parenteral Prostacyclins to Oral Selexipag in Pulmonary Arterial Hypertension.

Short interest: 19.04% of float, squeeze risk: MODERATE

368 PubMed publications found for Gossamer Bio

<article class="bts-verified-summary" data-ticker="GOSS">
<p>Gossamer Bio (GOSS) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-2">[2]</a></sup>, including 1 Phase 2<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>GOSS has 6 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-3">[3]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Gossamer+Bio%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Gossamer+Bio%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-3">SEC EDGAR · 0001728117 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22GOSS%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001728117

Gossamer Bio (GOSS) — BioTechSigns Verified Summary

Gossamer Bio (GOSS) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[2], including 1 Phase 2[1].

GOSS has 6 Form 4 insider filings recorded at the SEC in the past 30 days[3].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Gossamer+Bio%22&aggFilters=status%3Arec%2Cact
[2] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Gossamer+Bio%22&aggFilters=status%3Arec%2Cact
[3] SEC EDGAR, 0001728117. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22GOSS%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.